Singapore, June 18 -- Japan-based startup Axcelead Drug Discovery Partners (DDP), Inc. has entered a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).

Lilly TuneLab is designed to accelerate early stage discovery by enabling participating biotech partners to access drug discovery models trained on decades of Lilly's proprietary research data.

Under this collaboration, Axcelead DDP will be able to enhance prediction of drug-like properties across small molecules and antibody therapeutics, including ADME, safety, and preclinical attributes, accelerating AI-driven drug discovery and development.

Lilly TuneLab uses federated learning to collaboratively improve predicti...